

Clinical Paper  
Orthognathic Surgery

# Long-term quality of life outcomes of maxillomandibular advancement osteotomy in patients with obstructive sleep apnoea syndrome

L. Pottel<sup>1</sup>, N. Neyt<sup>1</sup>, K. Hertegonne<sup>2</sup>,  
D. Pevernagie<sup>3,4</sup>, B. Veys<sup>1</sup>,  
J. Abeloos<sup>1</sup>, C. De Clercq<sup>1</sup>

<sup>1</sup>Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium; <sup>2</sup>Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; <sup>3</sup>Sleep Medicine Centre, Kempenhaeghe, Heeze, The Netherlands; <sup>4</sup>Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

L. Pottel, N. Neyt, K. Hertegonne, D. Pevernagie, B. Veys, J. Abeloos, C. De Clercq: Long-term quality of life outcomes of maxillomandibular advancement osteotomy in patients with obstructive sleep apnoea syndrome. *Int. J. Oral Maxillofac. Surg.* 2019; 48: 332–340. © 2018 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

**Abstract.** This study was performed to evaluate the long-term impact of maxillomandibular advancement (MMA) surgery on the apnoea–hypopnoea index (AHI) and quality of life (QoL) in patients with obstructive sleep apnoea syndrome (OSAS). The medical files of 12 OSAS patients who underwent MMA by one surgeon between 1995 and 1999 were reviewed retrospectively. Patients received a clinical assessment, polysomnography, and QoL questionnaires as part of routine care preoperatively ( $n = 12$ ), within 2 years postoperative ( $n = 12$ ), and again in 2016 ( $n = 9$ ). A successful surgical outcome was defined as an AHI decrease of  $>50\%$  with  $<20$  events/h. Of the 66.7% (8/12) of patients who were initially cured, 66.7% (4/6) remained stable at a median follow-up of 19 years. Only the two patients with the highest AHI showed abnormal Epworth Sleepiness Scale scores. After convalescence, most patients reported stable symptomatic improvement. Aesthetic changes were found acceptable and all but one patient stated that they would undergo the surgery again. It is concluded that MMA is a safe and effective procedure. Ageing and weight gain might counterbalance the positive effects of surgery in the long term. It is therefore suggested that re-evaluation every 5 years should be scheduled, since a spontaneous AHI increase over time does not seem to be reflected by symptomatic changes.

**Key words:** obstructive sleep apnoea syndrome; long-term; maxillomandibular advancement osteotomy; quality of life; apnoea–hypopnoea index.

Accepted for publication  
Available online 19 October 2018

Obstructive sleep apnoea syndrome (OSAS) is highly prevalent in the general population<sup>1-3</sup>. It is characterized by chronic sleep deprivation due to recurrent respiratory cessation for 10 seconds or more during sleep. Patients complain of snoring, headaches, daytime sleepiness, and reduced concentration. OSAS patients are typically middle-aged, obese patients who often present with cardiometabolic comorbidities<sup>1,4</sup>.

Non-invasive treatment consists of weight control, adopting a supine sleep position, and the use of sedatives, alcohol, or cigarettes. Mechanical measures include sleeping with a continuous positive airway pressure (CPAP) device, which is currently considered the gold standard, or oral appliances that pull the tongue forward by moving the mandible anteriorly, and in that way dilating the airway. However, these devices might be tolerated poorly by patients in the long term. Moreover, relapse occurs immediately after treatment withdrawal<sup>5-7</sup>.

Surgical interventions such as tracheostomy, uvulopalatopharyngoplasty (UPPP), or upper airway correction have also been suggested, although results are variable. The efficacy of surgical maxillofacial osteotomies, on the other hand, has been widely reported. Bimaxillary advancement surgery increases the skeletal volume of the face, enlarging the airway space<sup>1,8,9</sup>. Despite its documented success, surgery is not yet considered to be standard treatment because of the lack of long-term studies examining the impact of the jaw correction at  $\geq 5$  years post-surgery<sup>5</sup>.

The aim of this study was to describe the quality of life (QoL) outcome over a period of almost 20 years after maxillomandibular advancement (MMA) surgery. The change in apnoea-hypopnoea index (AHI) and other relevant parameters associated with OSAS are also reported.

## Material and methods

### Patient population

This study was a retrospective review of patient medical files. Twelve OSAS patients who were consecutively treated with MMA by a single surgeon (CDC) at the Ghent University Hospital or AZ Sint-Jan Brugge-Oostende AV between November 1995 and December 1999 for clinically diagnosed OSAS were included. For inclusion, the patients had to have received clinical assessments, polysomnography (PSG), and QoL questionnaires as part of routine care preoperatively

( $n = 12$ ), within 2 years postoperative ( $n = 12$ ), and again in 2016 ( $n = 9$ ) as part of the routine long-term follow-up program organized by the department. The study was approved by the local ethics committees. All patients provided written informed consent.

At the time, MMA surgery was performed under general anaesthesia and included a bilateral sagittal split osteotomy (BSSO) of the mandible alone, or bimaxillary surgery with or without a genioplasty, as judged by the treating physician. A BSSO of the mandible was performed and fixed with three bicortical screws (Titamed, Antwerp, Belgium) on both sides. In the case of bimaxillary surgery, the mandible-first principle was employed. First the mandible was advanced by at least 10 mm. The maxilla was then fixed in its new position with four L-shaped miniplates (Titamed, Antwerp, Belgium) after a standard Le Fort I osteotomy with linear advancement or counterclockwise rotation in a new correct class I occlusion. An additional chin osteotomy was performed in only two patients.

PSG, as the gold standard to clinically diagnose OSAS patients, was performed overnight shortly after the clinical work-up, at the hospital where prior PSGs had also been performed, eliminating intercentre variability for individual patients. The participating centres were the Department of Respiratory Medicine, Ghent University Hospital ( $n = 8$ ), the Department of Pneumology, AZ Groeninge Kortrijk ( $n = 1$ ), and the Department of Pneumology, AZ Sint-Jan Brugge-Oostende AV ( $n = 1$ ).

OSAS severity was graded as 'absent' (AHI 0-4), 'mild' (AHI 5-14), 'moderate' (AHI 15-30), or 'severe' (AHI  $>30$ )<sup>10</sup>. Moreover, in accordance with the definition most often used in the literature<sup>11-14</sup>, a successful surgical outcome was defined as a decrease in AHI of  $>50\%$  with  $<20$  events/h<sup>11</sup>. Treatment failure was defined as a persistent AHI of  $\geq 30$ /h after MMA surgery<sup>15</sup>.

A cone beam computed tomography (CBCT) scan was taken of all patients as part of the long-term follow-up consultation, using a standardized scanning protocol (i-CAT; Imaging Sciences International, Inc., Hatfield, PA, USA), as described in detail by Guijarro-Martinez and Swennen<sup>16,17</sup>.

All DICOM data were viewed using the picture archiving and communication system (PACS) at default settings. Airway length (i.e., from posterior nasal spine to the base of the epiglottis), and the anteroposterior (AP) and lateral (LAT) width

of the smallest airway area were measured by a single investigator using the freehand tool incorporated in the PACS software, and according to cephalometric landmarks described by Abramson et al.<sup>18</sup>. Volumetric measurements of the total upper airway and its sub-regions were obtained using Brainlab iPlan software (Brainlab, Munich, Germany), according to the validated cephalometric landmarks as published by Guijarro-Martinez and Swennen<sup>17</sup>.

Patient QoL was rated with the OSAS questionnaire at all time points. This registers the impact of OSAS treatment(s) on the most common complaints (i.e., headache, blood pressure, daytime sleepiness, night-time awakening, concentration, frequent nocturnal diuresis, snoring, sexual activity, facial aesthetics, and self-confidence), based on a numerical scale from -5 to +5, with negative and positive values indicating worsening and improvement of symptoms, respectively.

The Epworth Sleepiness Scale (ESS) is a standardized validated questionnaire measuring the level of daytime sleepiness. The patient is asked to rate the chance of falling asleep in eight different daily life situations. A higher score corresponds to a higher level of daytime sleepiness, with a cut-off of  $\geq 10/24$  considered to be abnormal<sup>19,20</sup>.

### Statistical analysis

A descriptive analysis was performed, with presentation of the data as the median and interquartile range (IQR) or minimum-maximum range (range). Spearman correlation was used to examine potential correlations between AHI, ESS, body mass index (BMI), and other relevant parameters. The Mann-Whitney *U*-test was applied to examine potential differences between successful and unsuccessful postoperative outcomes. The Wilcoxon signed rank test was used to examine the change in oxygen values at the different time points. All analyses were performed using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA).

## Results

### Study population

Twelve patients had MMA surgery in the 1990s, of whom nine completed the long-term re-evaluation at the department. Two patients died before the long-term re-evaluation. One patient was unable to attend the department for objective re-evalua-

tion, but stated that she had no subjective complaints and was not receiving any type of OSAS treatment at the time.

The demographic and clinical characteristics of the study patients are shown in Table 1. Ten of the 12 patients were male. The median age at the time of MMA surgery was 43.5 years, ranging from 34 to 63 years. Ten patients presented with a class II, retrognathic profile, and two patients had a class I occlusion, without further skeletal malpositioning. All 12 patients had tried CPAP treatment prior to MMA surgery, and one had also tried an oral appliance. Two patients had undergone surgical interventions – genioglossus–tuberculum advancement in one and UPPP, tracheostomy, and septoplasty in the other – which proved unsuccessful. All patients requested a long-term, permanent solution, most often because of CPAP intolerance.

Two patients had a BSSO, six had a BSSO in combination with Le Fort I (LFI) surgery, and two had a LFI, BSSO and genioplasty. One patient also had a septum correction at the time of bimaxillary surgery. The surgical plan could not be retrieved for two patients.

The median follow-up of the nine patients who attended long-term re-evaluation was 19 years (range 14–20 years), and their median age was 62 years (range 49–82 years). At long-term follow-up, no patient complained of neurosensory sequelae. One patient had suffered dentoalveolar relapse towards the initial malocclusion. No patient expressed subjective complaints of temporomandibular joint problems.

Seven patients smoked at the time of MMA, two of whom had continued this habit. At the latest follow-up, the patients reported consuming a median of 14 units (range 0–25 units) of alcoholic beverages and 42 units (range 14–49 units) of caffeinated drinks per week. Five of the nine patients suffered from diabetes and seven took medications for cardiovascular morbidities.

#### Apnoea–hypopnoea index (AHI) and oxygen saturation (SaO<sub>2</sub>)

The change in AHI over time is presented in Table 2. Of the 12 patients, eight (66.7%) had a successful outcome (i.e., a decrease in AHI of >50% and <20 events/h), three had an unsuccessful outcome, and MMA surgery failed in one patient (i.e., a persistent AHI of ≥30/h after MMA surgery). Immediately postoperative, 25% of these 12 patients were categorized as normal, 41.7% as having

mild OSAS, and 25% as having moderate OSAS. One patient worsened postoperatively and was still categorized as having severe OSAS.

At a median follow-up of 19 years, four of the nine patients evaluated (44.4%), or four of the six initially successful patients (66.7%), maintained a successful outcome. Of these four successful patients, one had a normal AHI and three patients showed mild OSAS. The remaining two initially successful patients relapsed to preoperative AHI values; one had moderate OSAS and the other had severe OSAS. With regard to the other three re-evaluated patients, two had a complete relapse to preoperative values after an unsuccessful surgical outcome. The patient for whom treatment failed completely restarted CPAP treatment approximately 6 months postoperative. At present, he continues to suffer from severe OSAS and attends bi-annual close follow-up.

MMA surgery resulted in a significant increase in minimal oxygen saturation ( $P = 0.010$ ) and significantly reduced oxygen levels below 88% immediately postoperative ( $P = 0.021$ ). Only a trend towards significance of the latter result was seen at long-term postoperative ( $P = 0.091$ ) (data not shown). Moreover, no significant difference in preoperative oxygen saturation values was observed between patients with successful and unsuccessful outcomes (Table 3).

The patients presented a median preoperative BMI of 28.1 kg/m<sup>2</sup> (range 24.5–35.0 kg/m<sup>2</sup>). After approximately 19 years of follow-up, median BMI was 29.9 kg/m<sup>2</sup> (range 25.2–36.1 kg/m<sup>2</sup>).

As presented in Table 3, no significant difference ( $P > 0.05$ ) in age, AHI, BMI, oxygen saturation, sleep efficiency, or smoking or alcohol habits could be found between patients with a successful treatment outcome and those with an unsuccessful treatment outcome immediately postoperative. In patients whose treatment remained successful at long-term evaluation, a trend towards significantly older age, higher average SaO<sub>2</sub>, and lower AHI was observed in comparison to preoperative values. However, they did not significantly differ in preoperative parameters in comparison to those who relapsed. A trend towards significantly higher AHI, higher BMI, and lower sleep efficiency was found in the unsuccessful group in comparison to the successful group at long-term assessment.

Spearman correlation indicated a significant positive correlation between AHI and BMI ( $R_s = 0.733$ ,  $P = 0.025$ ). However, no significant correlation was found

between the changes in BMI versus in AHI between T2 and T0, indicating that weight gain was not the only factor that contributed to the AHI relapse. A significant inverse correlation was found between AHI and alcohol use ( $R_s = -0.778$ ,  $P = 0.039$ ); however, this effect disappeared when combined with BMI in a general linear model with AHI as the dependent variable. No significant correlation was found between AHI and age, sex, social status, presence of diabetes or cardiovascular comorbidities, smoking, and stress ( $P > 0.05$ ).

#### Upper airway dimensions

Airway dimensions of the nine patients re-evaluated at long-term post MMA surgery are presented in Table 4. Spearman correlation did not indicate an association between upper airway dimensions and AHI, except for a significant negative correlation between lateral width at the smallest airway area and AHI ( $R_s = 0.707$ ,  $P = 0.018$ ). Comparison of upper airway volume between successful and unsuccessful patients (i.e., failure, relapse) showed a trend towards a larger oropharyngeal volume in successful patients ( $P = 0.050$ ). No significant difference was found in airway length or AP/LAT width at the smallest area between the two groups.

#### Quality of life

The median ESS score at long-term follow-up was 5 (range 1–13). As presented in Fig. 1, only the two patients with the highest AHI scores, indicating severe OSAS, showed abnormal ESS scores. The seven other patients evaluated showed no subjective complaints that could be related to OSAS.

Spearman correlation indicated no significant correlation between AHI and ESS ( $P = 0.145$ ). Likewise, no significant correlation was found between BMI and ESS ( $P = 0.203$ ).

On average, patients rated the impact of OSAS on their daily life prior to surgery as 8.4 on a scale of 1–10, with 10 being the worst possible negative impact. Immediately postoperative, they reported improvements in symptoms of headache (median 4, range 0 to 4), blood pressure (median 1, range 0 to 5), daytime sleepiness (median 4, range 1 to 5), concentration (median 2, range –1 to 5), insomnia (median 3, range 0 to 5), nycturia (median 5, range 4 to 5), snoring (median 4, range 3 to 5), and sexual relationship (median 0.5, range 0 to 3). Also, they did not report

Table 1. Demographic and clinical characteristics of the study patients.

| Patient | Sex | Skeletal characteristics  | Other interventions                       | Age at MMA (years) | Follow-up (years) | Reason for MMA  | Age at follow-up (years) | Planned MMA procedure                                       |
|---------|-----|---|---|--------------------|-------------------|---|--------------------------|---|
| 1       | M   | Class II, retrognathic  | CPAP                                      | 63                 | 19                | Patient initiative, request for long-term solution  | 82                       | BSSO (mm ND)  |
| 2       | M   | Class II, retrognathic maxilla, mandibular hypoplasia, narrow oropharyngeal PAS, large tongue, long soft palate | CPAP                                      | 47                 | 19                | CPAP intolerance, limitation for travelling abroad, request for more comfortable solution at older age  | 67                       | LFI (8 mm)<br>BSSO (12 mm)<br>genioplasty (5 mm)            |
| 3       | M   | Class II, retrognathic maxilla, mandibular hypoplasia, narrow naso-, oro-, and hypopharyngeal PAS               | CPAP                                      | 43                 | 19                | CPAP intolerance towards the sound of the apparatus   | 62                       | BSSO (mm ND)  |
| 4       | M   | Retrognathic maxilla, retrognathic mandible, narrow PAS, low palate   | CPAP                                      | 40                 | 18                | CPAP intolerance, difficult patient compliance  | 59                       | LFI (12 mm)<br>BSSO (12 mm)<br>Septum correction            |
| 5       | M   | Class II, retrognathic maxilla, retrognathic mandible, narrow PAS, low position of the hyoid                    | CPAP                                      | 41                 | 20                | CPAP intolerance, pulling off mask during sleep   | 61                       | LFI (12 mm)<br>BSSO (12 mm)<br>genioplasty (2 mm intrusion) |
| 6       | M   | Class II, retrognathic  | CPAP                                      | 51                 | 16                | CPAP intolerance, hinders falling asleep  | 68                       | LFI (12 mm)<br>BSSO (11 mm)                                 |
| 7       | M   | Retrognathic maxilla, retrognathic mandible, narrow oro- and hypopharyngeal PAS, large uvula, short neck        | CPAP, activator                           | 44                 | 20                | CPAP and activator failed to provide efficient result; limitation for travelling with a motorcycle, intolerance from the partner towards the sound of the apparatus | 64                       | LFI (mm ND)<br>BSSO (mm ND)                                 |
| 8       | M   | Class I   | CPAP                                      | 34                 | 18                | ND  | 52                       | LFI (10 mm)<br>BSSO (9 mm)                                  |
| 9       | M   | Class II, retrognathic  | CPAP                                      | 35                 | 14                | CPAP intolerance, persistent sinusitis, bronchitis  | 49                       | LFI (10 mm)<br>BSSO (10 mm)                                 |
| 10      | F   | Class I, narrow PAS, hypopharyngeal obstruction, no skeletal malpositioning                                     | CPAP, genioglossus-tuberculum advancement | 40                 | NA                | CPAP intolerance, sinus-related problems  | NA                       | ND  |
| 11      | M   | Class II, retrognathic  | CPAP                                      | 57                 | NA                | ND  | NA                       | ND  |
| 12      | F   | Moon face, retrognathic maxilla, retrognathic mandible, narrow PAS, thickened palate, normal occlusion          | CPAP, UPPP, tracheostomy, septoplasty     | 47                 | NA                | CPAP intolerance, acute sinusitis with clogging of the cannulae   | NA                       | LFI (mm ND)<br>BSSO (12 mm)                                 |

BSSO, bilateral sagittal split osteotomy; CPAP, continuous positive airway pressure; F, female; LFI, Le Fort I; M, male; MMA, maxillomandibular advancement; NA, not applicable; ND, not determined; PAS, pharyngeal airway space; UPPP, uvulopalatopharyngoplasty.

Table 2. Change in AHI following surgery for the 12 OSAS patients who underwent MMA<sup>a</sup>. T0: preoperative; T1: immediately postoperative, T2: long-term postoperative (median of 19 years).

| Patient | AHI   |      |       | $\Delta$ T1 – T0 (%) | Outcome <sup>b</sup> | $\Delta$ T2–T0 (%) | Outcome <sup>b</sup> |
|---------|-------|------|-------|----------------------|----------------------|--------------------|----------------------|
|         | T0    | T1   | T2    |                      |                      |                    |                      |
| 1       | 31.0  | 5.0  | 5.1   | 83.9                 | Successful           | 83.5               | Successful           |
| 2       | 32.0  | 6.0  | 29.4  | 81.3                 | Successful           | 8.1                | Unsuccessful         |
| 3       | 26.0  | 19.0 | 22.5  | 26.9                 | Unsuccessful         | 13.5               | Unsuccessful         |
| 4       | 64.0  | 0.0  | 69.2  | 100.0                | Successful           | –8.1               | Failure              |
| 5       | 50.0  | 86.0 | 49.0  | –72.0                | Failure              | 2.0                | Failure              |
| 6       | 117.0 | 20.0 | 106.9 | 82.9                 | Unsuccessful         | 8.6                | Failure              |
| 7       | 55.0  | 0.0  | 6.9   | 100.0                | Successful           | 87.5               | Successful           |
| 8       | 28.0  | 7.0  | 2.9   | 75.0                 | Successful           | 89.6               | Successful           |
| 9       | 92.0  | 9.7  | 11.4  | 89.5                 | Successful           | 87.6               | Successful           |
| 10      | 31.0  | 3.0  | ND    | 90.3                 | Successful           | ND                 | ND                   |
| 11      | 84.0  | 21.0 | ND    | 75.0                 | Unsuccessful         | ND                 | ND                   |
| 12      | 121.0 | 9.0  | ND    | 92.6                 | Successful           | ND                 | ND                   |

AHI, apnoea–hypopnoea index; MMA, maxillomandibular advancement; ND, not determined; OSAS, obstructive sleep apnoea syndrome.

<sup>a</sup>Two patients died and one patient was lost to follow-up before quantitative evaluation at T2.

<sup>b</sup>According to the definition of Lye et al.<sup>11</sup>, the surgical outcome is successful when the AHI reduction is at least 50% with <20 events/hour. "Unsuccessful" outcome was defined as fulfilling one of those two criteria. Treatment failure is defined as a persistent AHI of  $\geq 30$ /h after MMA surgery<sup>15</sup>.

noticeable facial changes, either in a positive or a negative sense. At approximately 19 years postoperative, the patients stated improvements in all previously reported symptoms, except for blood pressure (median  $-0.5$ , range  $-1$  to  $2$ ), nycturia (median  $0$ , range  $-3$  to  $4$ ), and sexual activity (median  $0$ , range  $-4$  to  $3$ ) (Fig. 2). All but one patient stated that they would choose the surgery again, or recommend the procedure to friends and family with similar health problems.

## Discussion

In this study, eight of 12 patients (66.7%) showed a successful postoperative outcome based on a reduction in AHI of 50% with <20 events/h, which remained stable in four out of six (66.7%) initially cured patients after a median of 19 years postoperative. The follow-up period was uneventful, except for one patient who suffered a relapse of the initial malocclusion. Daytime sleepiness, as measured with the ESS, was within normal limits for all but two patients, both suffering from severe OSAS. A significant correlation was found between AHI and BMI, although not between AHI and ESS. An improvement in symptoms of snoring, headache, blood pressure, daytime sleepiness, concentration, insomnia, nycturia, and sexual activity was reported by all patients immediately postoperative. Comparable results were found at long-term re-evaluation, except for blood pressure, nycturia, and sexual activity. Patient satisfaction regarding aesthetic changes and improvements in QoL was high.

The results regarding the AHI, both short-term and long-term postoperative, are in agreement with those of a meta-analysis by Holty and Guillemineault, who reported a successful outcome after MMA surgery ranging between 65% and 100%, with a pooled surgical success rate of 86% based on 627 patients included in 53 separate publications<sup>13</sup>. Two recent publications, one by Vigneron et al. and the other by de Ruiter et al., described a successful outcome immediately postoperative in 85.7% of 34 patients and 71.0% of 62 patients, respectively, when applying the same definition<sup>12,21</sup>. Younger age, lower BMI, lower preoperative AHI, and a higher degree of maxillary advancement have been described as predictors of surgical success<sup>13,22,23</sup>. However, no significant difference in preoperative age, BMI, or AHI values was found between patients with successful versus unsuccessful outcomes in the present study.

In this study, two of the three patients with an unsuccessful outcome complied with one of the criteria defined, but not the two criteria combined (an AHI decrease of  $>50\%$  with  $<20$  events/h). One patient with severe OSAS unfortunately worsened postoperatively (AHI change from 50 to 86 events/h).

After a median of 19 years postoperative, a permanent normalization of the AHI was observed in four of the six patients who were initially cured. The two patients who relapsed had an AHI comparable to preoperative values. Both patients had a significant weight gain ( $+4.1$  and  $+7.9$  kg/m<sup>2</sup>). Preoperatively, both had a retrognathic profile, with re-

spectively a massive tongue and long soft palate, and a low palate. However, only one of these patients suffered from abnormal daytime sleepiness as indicated by a score of 12 on the ESS.

Long-term failure of MMA surgery has been ascribed to weight gain, skeletal relapse, or aging<sup>24</sup>.

There was a trend towards a significantly lower BMI in successfully operated patients who remained stable, in comparison to those who relapsed. Also, there was a positive Spearman correlation between BMI and AHI values. However, this was not the case for the change in the two parameters over time, indicating that BMI was not the sole cause of surgical failure. Indeed, according to the Cleveland Family study, the influence of body weight and sex on disease incidence diminishes with increasing age<sup>25,26</sup>.

Surgical relapse after MMA surgery has been described to range between 7% and 20%<sup>27,28</sup>. In one study, advancements of  $>7$  mm were found to be associated with an increased tendency towards relapse<sup>28</sup>. In the present study sample, an average advancement of  $10.7 \pm 1.6$  mm for LFI and  $11.0 \pm 1.3$  mm for BBSO was performed in seven of the 12 patients. Unfortunately, due to the lack of two-dimensional (2D) cephalometric imaging pre- and immediately postoperative, potential skeletal relapse could not be calculated. In the current study, OSAS relapse might also have been attributable to aging, possibly associated with a downward sag of the soft tissue profile<sup>29</sup>. In this study, two of three patients with severe OSAS who reached the age of  $\geq 65$  years at follow-up had relapsed.

Table 3. Comparison of clinical characteristics of patients with successful and unsuccessful outcomes after MMA surgery, immediately postoperative (T1) and long-term postoperative (T2); data are presented as the median (interquartile range), age is presented as the median (range).

|                              | Immediately postoperative (T1) |                            |                                   |                   | Long-term postoperative (T2) |                              |                      |                            |                              |         |                             |
|------------------------------|--------------------------------|----------------------------|-----------------------------------|-------------------|------------------------------|------------------------------|----------------------|----------------------------|------------------------------|---------|-----------------------------|
|                              | Successful (n = 8)             |                            | Unsuccessful (n = 4) <sup>b</sup> |                   | Successful (n = 4)           |                              | Unsuccessful (n = 2) |                            |                              |         |                             |
|                              | Value prior to MMA surgery     | Value prior to MMA surgery | P-value                           |                   | Value prior to MMA surgery   | Value at long-term follow-up | P-value              | Value prior to MMA surgery | Value at long-term follow-up | P-value | P-value preop. <sup>a</sup> |
| Age (years)                  | 40.0 (32.0–62.0)               | 46.5 (40.0–57.0)           | 0.231                             | 37.0 (32.0–62.0)  | 58.0 (49.0–82.0)             | 0.068                        | 42.0 (40.0–44.0)     | 63.0 (59.0–67.0)           | 0.180                        | 0.481   | 0.643                       |
| AHI                          | 52.5 (31.8, 71.0)              | 67.0 (44.0, 92.3)          | 0.933                             | 52.5 (45.3, 64.3) | 6.0 (4.6, 8.0)               | 0.068                        | 48.0 (40.0, 56.0)    | 49.3 (39.4, 59.3)          | 0.655                        | 1.000   | 0.064                       |
| BMI (kg/m <sup>2</sup> )     | 27.6 (25.5, 29.5)              | 29.1 (25.1, 33.1)          | 0.794                             | 29.0 (27.2, 31.2) | 28.1 (27.1, 28.7)            | 0.465                        | 26.0 (25.5, 26.5)    | 32.0 (31.1, 32.8)          | 0.180                        | 0.355   | 0.064                       |
| Average SaO <sub>2</sub> (%) | 91.0 (90.5, 92.5)              | 90.0 (85.4, 94.3)          | 0.776                             | 91.0 (90.8, 91.5) | 94.4 (94.1, 94.8)            | 0.068                        | ND                   | ND                         | 0.147                        | 0.147   | 0.147                       |
| Sleep efficiency (%)         | 87.0 (71.5, 91.0)              | 70.0 (63.0, 77.5)          | 0.304                             | 87.0 (84.0, 89.0) | 77.0 (72.4, 82.7)            | 0.109                        | 76.5 (69.2, 83.7)    | 64.1 (63.0, 65.2)          | 0.655                        | 0.767   | 0.064                       |
| ESS                          | ND                             | ND                         | ND                                | ND                | 4.0 (2.5, 5.5)               | ND                           | ND                   | 6.5 (10, 12.0)             | ND                           | ND      | 0.814                       |
| Smoking (PY)                 | 17.5 (0.0, 24.0)               | 13.0 (4.0, 34.0)           | 0.795                             | 17.5 (12.8, 18.3) | 35.5 (0.0, 48.0)             | 0.102                        | 12.0 (6.0, 18.0)     | 20.0 (0.0, 40.0)           | 0.317                        | 0.814   | 0.814                       |
| Alcohol (units/week)         | 11.2 (0.0, 42.0)               | ND                         | ND                                | 13.7 (9.1, 18.4)  | 14.0 (14.0, 25.2)            | 0.180                        | 25.9 (17.9, 34.0)    | 8.1 (0.0, 16.1)            | 0.180                        | 0.643   | 0.554                       |

AHI, apnoea-hypopnoea index; BMI, body mass index; ESS, Epworth Sleepiness Scale; MMA, maxillomandibular advancement; PY, pack-years; SaO<sub>2</sub>, oxygen saturation.

<sup>a</sup>Successful vs. unsuccessful

<sup>b</sup>According to the definition of Lye et al.<sup>11</sup>, the surgical outcome is successful when the AHI reduction is at least 50% with <20 events/hour. “Unsuccessful” outcome was defined as fulfilling one of those two criteria. Treatment failure is defined as a persistent AHI of ≥30/h after MMA surgery (Blumen et al.<sup>15</sup> Otolaryngol Head Neck Surgery).

Surgical success was only partly reflected in the reported QoL scores. Spearman correlation indicated no significant correlation between AHI and ESS. Only the two patients with the highest AHI values reported abnormal daytime sleepiness. This discrepancy is, however, in agreement with the literature<sup>11,21,30</sup>. Also, comparable to immediately postoperative, all but one patient reported improvements in OSAS-related symptoms. However, the effect on blood pressure, nycturia, and sexual activity had diminished by the latest follow-up, which could of course be attributed to older age. Only the patient with the highest AHI of 106.9/h reported a worsening of all of these symptoms in comparison to the immediate postoperative period. The discrepancy between OSAS severity and subjective feelings of QoL could indicate that patients adapt to their symptoms. Furthermore, most of these patients were not taking part in an active working life anymore, which could also have had an effect on subjective feelings of QoL.

Hudgel stated that although PSG is still the gold standard for diagnosing OSAS, the AHI should not be the sole indicator to determine the required patient care<sup>31</sup>. Symptoms of daytime sleepiness, sleep time and quality, BMI, (oro) pharyngeal anatomy, and certain health behaviours such as cigarette smoking or alcohol use should also be taken into account<sup>25,31</sup>. Moreover, since patients might ascribe their symptoms to the normal process of aging, thereby minimizing the severity, it is suggested that re-evaluation every 5 years postoperative should be integrated into the routine care in this patient population, in view of the severity of the diagnosis.

The study results should be interpreted with caution due to certain limitations. First, the sample size is relatively small, although the study included all consecutive patients who had MMA surgery in a 5-year period performed by a single surgeon at a time when MMA surgery was just being introduced as a treatment option for OSAS.

Second, the two female patients were both lost to follow-up. Although the male to female ratio for OSAS patients is 2:1, the study results may not be generalizable to the female population. Vigneron et al. suggested that women might perform better in the long-term; however, they suggested confirmation of this finding in a trial with a larger population of female OSAS patients<sup>21</sup>. Also, Silva et al. concluded that QoL, as mea-

Table 4. Presentation of airway dimensions and volume, based on the CBCT scan obtained at long-term postoperative (T2)<sup>a</sup>.

| Patient | Total airway volume (mm <sup>3</sup> ) | Nasopharyngeal volume (mm <sup>3</sup> ) | Oropharyngeal volume (mm <sup>3</sup> ) | Hypopharyngeal volume (mm <sup>3</sup> ) | Smallest LAT/AP width (mm) | Airway length (corrected for height <sup>b</sup> ) (mm) |
|---------|--|--|---|--|----------------------------|---|
| 1       | 47,122                                 | 10,885                                   | 27,417                                  | 8820                                     | 6.80                       | 71 (0.040)  |
| 2       | 30,413                                 | 9276                                     | 15,603                                  | 5534                                     | 3.80                       | 68 (0.040)  |
| 3       | 34,061                                 | 8551                                     | 18,398                                  | 7112                                     | 5.75                       | 65 (0.037)  |
| 4       | 32,907                                 | 7671                                     | 20,338                                  | 4898                                     | 23.00                      | 76 (0.044)  |
| 5       | 50,041                                 | 8815                                     | 26,301                                  | 14,925                                   | 2.30                       | 79 (0.045)  |
| 6       | 46,799                                 | 9761                                     | 26,229                                  | 10,809                                   | 2.00                       | 77 (0.046)  |
| 7       | 42,580                                 | 11,515                                   | 23,228                                  | 7777                                     | 2.91                       | 77 (0.046)  |
| 8       | 37,229                                 | 7284                                     | 26,490                                  | 3455                                     | 4.67                       | 75 (0.041)  |
| 9       | 48,194                                 | 6405                                     | 35,822                                  | 5967                                     | 2.91                       | 87 (0.051)  |

AP, anteroposterior, CBCT, cone beam computed tomography; LAT, lateral.

<sup>a</sup> Volume measurements were performed in Brainlab iPlan, and according to validated cephalometric landmarks as published by Guijarro-Martinez and Swennen<sup>17</sup>. Airway dimensions were measured in PACS, and according to cephalometric landmarks as published by Abramson et al.<sup>18</sup>.

<sup>b</sup> Airway length corrected for height given in parenthesis.

sured with three different validated questionnaires, tends to be poorer only in female patients with severe OSA in a middle-aged to elderly cohort<sup>32</sup>.

Third, objective quantification of skeletal stability was not included. Three-dimensional (3D) volume measurement of the airway through CBCT measurement should nowadays be an integral part of preoperative work-up and postoperative evaluation of surgical success<sup>16,17,23</sup>. However, at the time of surgery, the technology of CBCT was not yet available. Preoperative 2D cephalometric images could not be retrieved, making quantitative comparison impossible. Also, superimposition of 2D cephalometric images on a 2D virtually reconstructed 3D CBCT image might introduce an important source of analysis bias<sup>33</sup>.

No association was found between a longer airway length or higher LAT/AP ratio and a higher AHI, as has been suggested previously in the literature, although the measurement landmarks have often been defined differently<sup>18,34,35</sup>. A non-significant trend towards larger oropharyngeal volumes was found in patients in whom the MMA surgery was still successful at long-term re-evaluation. However, the measured upper airway volumes in all study patients are comparable to normative data published by Schendel et al.<sup>36</sup>. Also, they are in agreement with airway volumes measured immediately post MMA surgery, as reported previously by our team<sup>23</sup>. This could indicate that skeletal relapse might not be the cause of OSAS relapse in the long-term.

Future longitudinal studies incorporating CBCT images prior to and at different time points postoperative could provide novel landmark evidence regarding the airway and orofacial adaptive changes that could impact the management of OSAS.

Fourth, neck circumference was not measured as a parameter. No such data were available preoperatively, hindering quantitative comparison. A neck circumference of 40 cm or more was considered an indication for surgery by Ferguson et al. in 1995, and a recent paper by de Ruiter et al. (2017) also suggests that neck girth might predict treatment failure in MMA. Therefore neck circumference will be incorporated in future anthropometric measurements in our department<sup>12,37</sup>.

Fifth, patients were asked to complete the same questionnaire on current symptom severity that was applied 20 years ago, rating a comparison to the preoperative and immediate postoperative situation based on a numerical scale from -5 to +5. At present, there is no consensus on




Fig. 1. Quality of life, as measured with the Epworth Sleepiness Scale and the apnoea-hypopnoea index, of the nine patients re-evaluated at long-term follow-up.




Fig. 2. Impact of maxillomandibular advancement surgery on quality of life, as measured with the OSAS questionnaire, immediately postoperative and at long-term follow-up.

the best QoL instrument to apply in OSAS patients<sup>32,38</sup>. Since re-evaluation was performed at a median follow-up of 19 years, they might have forgotten the impact of their condition prior to surgery, and thus recall bias may be present.

In conclusion, MMA surgery is a safe and effective alternative to CPAP in the long-term treatment of OSAS patients. Weight gain can negatively influence the treatment outcome and should be monitored. Consequently, systematic re-evaluation annually or every 5 years should be considered in view of the seriousness of the condition, which is more prevalent in an older population, and since subjective complaints are not always in relation to OSAS severity.

**Acknowledgement.** We would like to thank Prof. em. Mark Van Hoecke for his time and kind support of this study.

**Funding.** This research did not receive any specific grant from funding agencies in the

public, commercial, or not-for-profit sectors.

**Competing interests.** The authors have no conflict of interest to declare.

**Ethical approval.** The study was approved by the Ghent University and AZ Sint-Jan Brugge Oostende ethics committees (B670201629138).

**Patient consent.** All patients provided written informed consent.

**References**

1. Blumen M, Vezina J, Pigot J, Chabolle F. Maxillomandibular advancement for obstructive sleep apnea syndrome. *Oper Tech Otolaryngol* 2012;**23**(1):60–6.
2. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-

- disordered breathing among middle-aged adults. *N Engl J Med* 1993;**328**(17):1230–5.
3. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M, Haba-Rubio J. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med* 2015;**3**:310–8.
4. Costello B, Posnick J. The role of maxillo-facial osteotomies in the treatment of obstructive sleep apnea. *Curr Opin Otolaryngol Head Neck Surg* 2003;**11**(4):267–74.
5. Downey R. *Obstructive sleep apnea treatment and management.* Medscape [Internet]; 2015. <http://emedicine.medscape.com> [Accessibility verified on 25/09/2018].
6. Zhu Y, Long H, Jian F, Lin J, Zhu J, Gao M, Lai W. The effectiveness of oral appliances for obstructive sleep apnea syndrome: a meta-analysis. *J Dent* 2015;**43**(12):1394–402.
7. Giles T, Lasserson T, Smith B, White J, Wright J, Cates C. Continuous positive airways pressure for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev* 2006;**25**(1)CD001106.
8. Waite P, Wooten V, Lachner J, Guyette RF. Maxillomandibular advancement surgery in 23 patients with obstructive sleep apnea syndrome. *J Oral Maxillofac Surg* 1989;**47**(12):1256–61.
9. Smatt Y, Ferri J. Retrospective study of 18 patients treated by maxillomandibular advancement with adjunctive procedures for obstructive sleep apnea syndrome. *J Craniofac Surg* 2005;**16**(5):770–7.
10. American Academic of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. *Sleep* 1999;**22**:667–89.
11. Lye KW, Waite PD, Meara D, Wang D. Quality of life evaluation of maxillomandibular advancement surgery for treatment of obstructive sleep apnea. *J Oral Maxillofac Surg* 2008;**66**:968–72.
12. de Ruiter MH, Apperloo RC, Milstein DM, de Lange J. Assessment of obstructive sleep apnoea treatment success or failure after maxillomandibular advancement. *Int J Oral Maxillofac Surg* 2017;**46**(11):1357–62.
13. Holty JE, Guillemainault C. Maxillomandibular advancement for the treatment of obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Med Rev* 2010;**14**:287–97.
14. Rubio-Bueno P, Landete P, Ardanza B, Vazquez L, Soriano JB, Wix R, Capote A, Zamora E, Ancochea J, Naval-Gías L. Maxillomandibular advancement as the initial treatment of obstructive sleep apnoea: is the mandibular occlusal plane the key? *Int J Oral Maxillofac Surg* 2017;**46**:1363–71.

15. Blumen MB, Buchet I, Meulien P, Hausser Hauw C, Neveu H, Chabolle F. Complications/adverse effects of maxillomandibular advancement for the treatment of OSA in regard to outcome. *Otolaryngol Head Neck Surg* 2009;**141**:591–7.
16. Guijarro-Martinez R, Swennen GR. Cone-beam computerized tomography imaging and analysis of the upper airway: a systematic review of the literature. *Int J Oral Maxillofac Surg* 2011;**40**:1227–37.
17. Guijarro-Martinez R, Swennen GR. Three-dimensional cone beam computed tomography definition of the anatomical subregions of the upper airway: a validation study. *Int J Oral Maxillofac Surg* 2013;**42**:1140–9.
18. Abramson Z, Susarla S, August M, Troulis M, Kaban L. Three-dimensional computed tomographic analysis of airway anatomy in patients with obstructive sleep apnea. *J Oral Maxillofac Surg* 2010;**68**:354–62.
19. Rosenthal LD, Dolan DC. The Epworth sleepiness scale in the identification of obstructive sleep apnea. *J Nerv Ment Dis* 2008;**196**(5):429–31.
20. Johns M. *The Epworth Sleepiness Scale*. Official website; 2015 . <http://epworthsleepinessscale.com/> [Accessibility verified on 25/09/2018].
21. Vigneron A, Tamisier R, Orset E, Pepin JL, Bettega G. Maxillomandibular advancement for obstructive sleep apnea syndrome treatment: long-term results. *J Craniomaxillofac Surg* 2017;**45**:183–91.
22. Zaghi S, Holty JE, Certal V, Abdullatif J, Guilleminault C, Powell NB, Riley RW, Camacho M. Maxillomandibular advancement for treatment of obstructive sleep apnea: a meta-analysis. *JAMA Otolaryngol Head Neck Surg* 2016;**142**:58–66.
23. Veys B, Pottel L, Mollemans W, Abeloos J, Swennen G, Neyt N. Three-dimensional volumetric changes in the upper airway after maxillomandibular advancement in obstructive sleep apnea patients and the impact on quality of life. *Int J Oral Maxillofac Surg* 2017;**46**(12):1525–32.
24. Riley RW, Powell NB, Li KK, Troell RJ, Guilleminault C. Surgery and obstructive sleep apnea: long-term clinical outcomes. *Otolaryngol Head Neck Surg* 2000;**122**:415–21.
25. Punjabi NM. The epidemiology of adult obstructive sleep apnea. *Proc Am Thorac Soc* 2008;**5**:136–43.
26. Tishler PV, Larkin EK, Schluchter MD, Redline S. Incidence of sleep-disordered breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. *JAMA* 2003;**289**:2230–7.
27. Pang KP, Rotenberg BW, Tucker Woodson B. *Advanced surgical techniques in snoring and obstructive sleep apnea*. Plural Publishing Inc.; 2013.
28. Darshan SV, Ronad YA, Kishore MS, Shetty KS, Rajesh M, Suman SD. Long term stability and relapse following mandibular advancement and mandibular setback surgeries: a cephalometric study. *J Int Oral Health* 2014;**6**:42–6.
29. Vasir NS, Robinson RJ. The mandibular third molar and late crowding of the mandibular incisors—a review. *Br J Orthod* 1991;**18**:59–66.
30. Weaver EM, Woodson BT, Steward DL. Polysomnography indexes are discordant with quality of life, symptoms, and reaction times in sleep apnea patients. *Otolaryngol Head Neck Surg* 2005;**132**:255–62.
31. Hudgel DW. Sleep apnea severity classification—revisited. *Sleep* 2016;**39**:1165–6.
32. Silva GE, Goodwin JL, Vana KD, Quan SF. Obstructive sleep apnea and quality of life: comparison of the SAQLI, FOSQ, and SF-36 questionnaires. *Southwest J Pulm Crit Care* 2016;**13**:137–49.
33. van Vlijmen OJ, Berge SJ, Bronkhorst EM, Swennen GR, Katsaros C, Kuijpers-Jagtman AM. A comparison of frontal radiographs obtained from cone beam CT scans and conventional frontal radiographs of human skulls. *Int J Oral Maxillofac Surg* 2009;**38**:773–8.
34. Susarla SM, Abramson ZR, Dodson TB, Kaban LB. Cephalometric measurement of upper airway length correlates with the presence and severity of obstructive sleep apnea. *J Oral Maxillofac Surg* 2010;**68**:2846–55.
35. Ogawa T, Enciso R, Shintaku WH, Clark GT. Evaluation of cross-section airway configuration of obstructive sleep apnea. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007;**103**:102–8.
36. Schendel SA, Jacobson R, Khalessi S. Airway growth and development: a computerized 3-dimensional analysis. *J Oral Maxillofac Surg* 2012;**70**:2174–83.
37. Ferguson KA, Ono T, Lowe AA, Ryan CF, Fleetham JA. The relationship between obesity and craniofacial structure in obstructive sleep apnea. *Chest* 1995;**108**:375–81.
38. Abma IL, van der Wees PJ, Veer V, Westert GP, Rovers M. Measurement properties of patient-reported outcome measures (PROMs) in adults with obstructive sleep apnea (OSA): a systematic review. *Sleep Med Rev* 2016;**28**:18–31.

Address:  
 dr. Lies Pottel  
 Clinical Research Coordinator  
 Division of Maxillofacial Surgery  
 Department of Surgery  
 AZ Sint-Jan Brugge-Oostende AV  
 Ruddershove 10  
 8000 Bruges  
 Belgium  
 Tel.: +32 (0)50 45 96 60  
 E-mail: Lies.Pottel@azsintjan.be